Related Experiment Videos
[Serum deoxythymidine kinase in hematological malignancy].
1Department of Internal Medicine, Branch Hospital, Nagoya University Medical School.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|December 1, 1988
Summary
A new deoxythymidine kinase (TK) assay reveals elevated TK activity in patients with hematological malignancies. This TK activity, originating from malignant cells, serves as a valuable tumor marker.
Area of Science:
- Biochemistry
- Oncology
- Hematology
Context:
- Hematological malignancies represent a significant global health burden.
- Accurate diagnostic and prognostic markers are crucial for effective patient management.
- Deoxythymidine kinase (TK) is an enzyme involved in DNA synthesis, often dysregulated in cancer.
Purpose:
- To evaluate a novel deoxythymidine kinase (TK) assay for its utility in diagnosing and monitoring hematological malignancies.
- To investigate the correlation between serum TK activity and disease status in patients with hematological cancers.
Summary:
- A new assay using 125I-iodo-deoxyuridine measured serum deoxythymidine kinase (TK) activity in 57 healthy individuals and 46 patients with hematological malignancies.
- Normal adult serum TK activity was low (<10 U/l), while patients exhibited significantly elevated levels, particularly in non-remission and acute phases.
- TK activity was higher in supernatants from leukemic cells compared to lymphocytes and spleen cells, suggesting a malignant cell origin.
Impact:
- The findings suggest that elevated serum TK activity, detected by this novel assay, can serve as a sensitive biomarker for tumor burden in hematological malignancies.
- This assay may offer a non-invasive method for disease monitoring and assessing treatment response.